Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: Results from a large German community-based observational cohort study

Figures & data

Table I. Demographics and baseline characteristics (n = 1777).

Characteristic	Value
Male/female, n (%)	1108/669 (62/38)
Median age, years (range)	64 (19–100)
≥ 70 years, %	27
≥ 75 years, %	12
Primary tumour in situ, n (%)	125 (7)
Metastatic site,* n (%)
Liver	1267 (71)
Lung	490 (28)
Bone	57 (3)
Other	457 (26)
Number of metastatic sites, n (%)
1	1145 (68)
> 1	529 (32)
ECOG performance status, n (%)
0–1	1554 (89)
≥ 2	191 (11)
(Neo)adjuvant chemotherapy, n (%)	776 (44)
Leucocytes, n (%)
< 8	1083 (63)
≥ 8	636 (37)

*One patient could have more than one metastatic site.

Table II. Overall response rate (ORR) using RECIST (version 1) by chemotherapy regimen used with bevacizumab (n = 1777).

Response, %	5-FU or capecitabine (n = 209)	Oxaliplatin (n = 327)	Irinotecan (n = 1142)	Other (n = 99)	Total (n = 1777)
ORR	54	65	61	52	60
Complete response	8	10	10	11	10
Partial response	46	55	51	41	51
Stable disease	33	26	27	33	28
Progressive disease	9	3	8	5	7
Not evaluable	3	6	5	9	5

Figure 1. PFS by initial chemotherapy regimen.

Figure 2. PFS by initial maintenance therapy.

Figure 3. OS by initial chemotherapy regimen.

Figure 4. OS by de-escalation strategy.

Figure 5. OS by maintenance therapy.